SEC-sourced researchBeta

NRIX

Nurix Therapeutics, Inc.

US markets

Data passport

CIK: 0001549595
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 2, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 11:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

NRIX · Exact amounts and source periods · USD
Period end	Revenue	Filing date
November 2023	76,987,000.0000	Jan 28, 2026
November 2024	54,549,000.0000	Jan 28, 2026
November 2025	83,980,000.0000	Jan 28, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
November 2025	83,980,000.0000	-264,457,000.0000	-249,465,000.0000	688,135,000.0000	149,388,000.0000	Jan 28, 2026
November 2024	54,549,000.0000	-193,569,000.0000	-172,584,000.0000	669,343,000.0000	142,350,000.0000	Jan 28, 2026
November 2023	76,987,000.0000	-143,948,000.0000	-81,365,000.0000	—	—	Jan 28, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$83.98M	November 2025	Jan 28, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$54.55M	November 2024	Jan 28, 2026	10-K
Net incomeNetIncomeLoss	-$264.46M	November 2025	Jan 28, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$249.47M	November 2025	Jan 28, 2026	10-K
Total assetsAssets	$688.14M	November 2025	Jan 28, 2026	10-K
Total liabilitiesLiabilities	$149.39M	November 2025	Jan 28, 2026	10-K

New filings

Explore methodology ↗